A practical field sheet

Safety Checklist

A cautious way to evaluate ibogaine treatment centers in Mexico: ask for evidence of screening, monitoring, emergency readiness, and honest limits before treating any promise as reassurance.

Questions are part of consent.

Hands reviewing information together while considering ibogaine treatment safety

Start here

Safety is a process, not a brochure.

Ibogaine has documented cardiac risk, including changes to the QT interval and potentially dangerous rhythm disturbances. The published safety literature on ibogaine-associated cardiac events is a reason to take pre-treatment screening and active monitoring seriously, not a reason to rely on broad assurances.

Use this checklist alongside the broader context on evaluating ibogaine options in Mexico. It is designed to help prospective clients and families identify questions a center should be able to answer clearly, with documentation and a realistic account of uncertainty.

Before any dose

1. Ask for a real medical screen.

“Medical screening” should mean more than a questionnaire. A safety-focused program should explain what it reviews, who reviews it, what findings change eligibility, and when it refers someone for further care.

ECG and cardiac history

Ask whether a recent ECG is required and how the result is interpreted before treatment. A cardiac history should account for known rhythm problems, fainting, structural heart disease, family history, and current symptoms.

This matters because long QT syndrome and QT prolongation are associated with a risk of dangerous arrhythmias; a center should not present heart screening as a ceremonial formality.

Electrolyte labs

Ask which laboratory tests are used, how recent they must be, and whether abnormal electrolytes are corrected and rechecked before proceeding. Potassium and magnesium can be relevant to cardiac electrical stability.

A clear answer should include what happens when labs are abnormal, rather than a generic statement that testing is available.

Medication and substance review

Ask for a careful review of prescribed medicines, over-the-counter products, supplements, and recent substance use. Interactions, withdrawal, sedation, and cardiac effects can all affect risk.

The FDA’s drug-interaction safety information reflects a basic principle: medication decisions should be reviewed in context, not reduced to a one-size-fits-all stop list.

Contraindications and deferral

Ask which medical and psychiatric circumstances lead the program to decline or defer treatment. A credible answer should acknowledge that some people may not be appropriate candidates and that uncertainty may require outside evaluation.

For comparison, program-level treatment information can help frame the questions, but it should never substitute for an individualized clinical review.

During treatment

2. Inspect the on-site safety plan.

A center should be able to describe its medical capabilities plainly: what equipment is on site, who is present, how long people are monitored, and who can recognize and respond to deterioration.

Continuous cardiac monitoring matters because an ECG taken only before treatment cannot show every rhythm change that may occur later. Ask whether monitoring is continuous, who watches it, and what specific escalation thresholds trigger action.

No vague contingencies

3. Confirm emergency transfer is more than a promise.

A remote assurance that “a hospital is nearby” is not the same as an emergency plan. Ask whether there is a documented transfer arrangement, which hospital receives patients, how transport is activated, and how records and handoff information travel with the patient.

Hospital pathway

Ask for a concrete description of the route from an on-site emergency to hospital care. The answer should cover transport, timing, communication, and who stays responsible during the transfer.

When comparing claims from different ibogaine treatment centers, note whether each one describes an actual process rather than simply naming emergency services.

Credentials without guesswork

Ask what physician and nursing presence means in practice: availability, scope of responsibility, and involvement in screening and monitoring. Do not infer qualifications from job titles, testimonials, or photos.

Our center comparison framework can help keep answers side by side so important gaps are not lost in marketing language.

The hard questions

4. Look for candor about adverse events.

Ask whether the center tracks adverse events, how it documents transfers or complications, and whether it can discuss what it changed after a problem. A program that treats every concern as an attack is not offering useful transparency.

Documented incident patterns have been associated with cardiac risk and with inadequate screening or monitoring. The clinical discussion of reported ibogaine fatalities underscores why a center’s policies should be specific about exclusion criteria, monitoring, and escalation.

For a separate view of location and access questions, where people receive ibogaine may be useful context, but a destination is not evidence of medical readiness.

The exit plan

5. Ask what happens after the monitored period.

Safety does not end when the acute session ends. Ask about discharge criteria, transportation, medication instructions, follow-up needs, and what symptoms require urgent evaluation after leaving the facility.

A practical plan should distinguish between general support and medical advice. It should also make room for the person’s existing clinicians when appropriate, rather than asking someone to navigate an uncertain recovery period alone.

Frequently asked questions

A checklist cannot make a risky situation safe.

Use these answers to prepare for conversations, not to replace individualized medical assessment.

What should a prospective client ask about emergency planning?

Ask whether the program has a written transfer process, which hospital it uses in an emergency, how transport is arranged, and how monitoring and records are handed over. A nearby hospital is not itself proof that a transfer pathway is workable.

Why does medication review matter before ibogaine?

Medication and substance use can affect heart rhythm, sedation, withdrawal risk, and interactions. A safety-focused assessment should account for prescribed drugs, non-prescription substances, and recent use. Information about the plant source of ibogaine does not answer those individualized safety questions.

Can a checklist guarantee safety?

No. A checklist cannot remove risk or replace individualized medical assessment. It can help identify unanswered questions and avoid treating reassuring marketing language as proof of preparedness. For the standards behind this approach, see the independent resource’s principles of caution and transparency.

Pause. Compare. Ask again.

Good questions do not guarantee an outcome. They can help make a decision less dependent on urgency, persuasion, or incomplete information.

Consider aftercare and integration